Technical Analysis for ERYP - Erytech Pharma S.A.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical ERYP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | -3.42% | |
| Outside Day | Range Expansion | -3.42% | |
| Oversold Stochastic | Weakness | -3.42% | |
| Narrow Range Bar | Range Contraction | -0.42% | |
| Doji - Bullish? | Reversal | -0.42% | |
| Stochastic Reached Oversold | Weakness | -0.42% | |
| Gapped Down | Weakness | -0.42% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2019
- Sector: Healthcare
- Industry: Biotechnology
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.
Medicine Biopharmaceutical Cancer Clinical Medicine Antineoplastic Drugs Leukemia Acute Lymphoblastic Leukemia Asparaginase Medicinal Products
Medicine Biopharmaceutical Cancer Clinical Medicine Antineoplastic Drugs Leukemia Acute Lymphoblastic Leukemia Asparaginase Medicinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ERYP news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 21.62 |
| 52 Week Low | 5.45 |
| Average Volume | 3,074 |
| 200-Day Moving Average | 9.1688 |
| 50-Day Moving Average | 7.9297 |
| 20-Day Moving Average | 7.5045 |
| 10-Day Moving Average | 7.268 |
| Average True Range | 0.3127 |
| ADX | 23.65 |
| +DI | 24.3106 |
| -DI | 38.3587 |
| Chandelier Exit (Long, 3 ATRs ) | 7.3719 |
| Chandelier Exit (Short, 3 ATRs ) | 8.0081 |
| Upper Bollinger Band | 8.1178 |
| Lower Bollinger Band | 6.8912 |
| Percent B (%b) | 0.15 |
| BandWidth | 16.34486 |
| MACD Line | -0.1876 |
| MACD Signal Line | -0.1719 |
| MACD Histogram | -0.0157 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.40 | ||||
| Resistance 3 (R3) | 7.44 | 7.36 | 7.35 | ||
| Resistance 2 (R2) | 7.36 | 7.28 | 7.35 | 7.33 | |
| Resistance 1 (R1) | 7.22 | 7.23 | 7.18 | 7.18 | 7.31 |
| Pivot Point | 7.14 | 7.14 | 7.13 | 7.13 | 7.14 |
| Support 1 (S1) | 7.00 | 7.06 | 6.96 | 6.96 | 6.83 |
| Support 2 (S2) | 6.92 | 7.01 | 6.91 | 6.81 | |
| Support 3 (S3) | 6.78 | 6.92 | 6.80 | ||
| Support 4 (S4) | 6.74 |
